480 related articles for article (PubMed ID: 28685687)
21. Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.
Moss DE; Perez RG
Curr Alzheimer Res; 2021; 18(13):1010-1022. PubMed ID: 34911424
[TBL] [Abstract][Full Text] [Related]
22. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease.
Chierrito TPC; Pedersoli-Mantoani S; Roca C; Requena C; Sebastian-Perez V; Castillo WO; Moreira NCS; Pérez C; Sakamoto-Hojo ET; Takahashi CS; Jiménez-Barbero J; Cañada FJ; Campillo NE; Martinez A; Carvalho I
Eur J Med Chem; 2017 Oct; 139():773-791. PubMed ID: 28863358
[TBL] [Abstract][Full Text] [Related]
23. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents.
Ambure P; Kar S; Roy K
Biosystems; 2014 Feb; 116():10-20. PubMed ID: 24325852
[TBL] [Abstract][Full Text] [Related]
24. Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease.
Taylor P
Neurology; 1998 Jul; 51(1 Suppl 1):S30-5; discussion S65-7. PubMed ID: 9674760
[TBL] [Abstract][Full Text] [Related]
25. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
Gurung AB; Aguan K; Mitra S; Bhattacharjee A
J Biomol Struct Dyn; 2017 Jun; 35(8):1729-1742. PubMed ID: 27410776
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease.
Toda N; Tago K; Marumoto S; Takami K; Ori M; Yamada N; Koyama K; Naruto S; Abe K; Yamazaki R; Hara T; Aoyagi A; Abe Y; Kaneko T; Kogen H
Bioorg Med Chem; 2003 May; 11(9):1935-55. PubMed ID: 12670645
[TBL] [Abstract][Full Text] [Related]
27. In silico design and search for acetylcholinesterase inhibitors in Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity.
da Silva VB; de Andrade P; Kawano DF; Morais PA; de Almeida JR; Carvalho I; Taft CA; da Silva CH
Future Med Chem; 2011 Jun; 3(8):947-60. PubMed ID: 21707398
[TBL] [Abstract][Full Text] [Related]
28. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
29. Possibility of Acetylcholinesterase Overexpression in Alzheimer Disease Patients after Therapy with Acetylcholinesterase Inhibitors.
Kračmarová A; Drtinová L; Pohanka M
Acta Medica (Hradec Kralove); 2015; 58(2):37-42. PubMed ID: 26455564
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of donepezil administration on acetylcholinesterase activity and altered redox homeostasis in Alzheimer's disease.
Atukeren P; Cengiz M; Yavuzer H; Gelisgen R; Altunoglu E; Oner S; Erdenen F; Yuceakın D; Derici H; Cakatay U; Uzun H
Biomed Pharmacother; 2017 Jun; 90():786-795. PubMed ID: 28427041
[TBL] [Abstract][Full Text] [Related]
31. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease.
Villarroya M; García AG; Marco JL
Curr Pharm Des; 2004; 10(25):3177-84. PubMed ID: 15544507
[TBL] [Abstract][Full Text] [Related]
32. Biocomputational Screening of Natural Compounds against Acetylcholinesterase.
Ahmad SS; Khan MB; Ahmad K; Lim JH; Shaikh S; Lee EJ; Choi I
Molecules; 2021 Apr; 26(9):. PubMed ID: 33946559
[TBL] [Abstract][Full Text] [Related]
33. Use of ligand-based pharmacophore modeling and docking approach to find novel acetylcholinesterase inhibitors for treating Alzheimer's.
Dhanjal JK; Sharma S; Grover A; Das A
Biomed Pharmacother; 2015 Apr; 71():146-52. PubMed ID: 25960230
[TBL] [Abstract][Full Text] [Related]
34. Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease.
Michalska P; Buendia I; Del Barrio L; Leon R
Curr Top Med Chem; 2017; 17(9):1027-1043. PubMed ID: 27697052
[TBL] [Abstract][Full Text] [Related]
35. Myrtenal inhibits acetylcholinesterase, a known Alzheimer target.
Kaufmann D; Dogra AK; Wink M
J Pharm Pharmacol; 2011 Oct; 63(10):1368-71. PubMed ID: 21899553
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease.
Li RS; Wang XB; Hu XJ; Kong LY
Bioorg Med Chem Lett; 2013 May; 23(9):2636-41. PubMed ID: 23511019
[TBL] [Abstract][Full Text] [Related]
37. Machine learning models to select potential inhibitors of acetylcholinesterase activity from SistematX: a natural products database.
Herrera-Acevedo C; Perdomo-Madrigal C; Herrera-Acevedo K; Coy-Barrera E; Scotti L; Scotti MT
Mol Divers; 2021 Aug; 25(3):1553-1568. PubMed ID: 34132933
[TBL] [Abstract][Full Text] [Related]
38. Computational analysis of novel drugs designed for use as acetylcholinesterase inhibitors and histamine H3 receptor antagonists for Alzheimer's disease by docking, scoring and de novo evolution.
Chen PY; Tsai CT; Ou CY; Hsu WT; Jhuo MD; Wu CH; Shih TC; Cheng TH; Chung JG
Mol Med Rep; 2012 Apr; 5(4):1043-8. PubMed ID: 22267207
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
40. Traditional Chinese medicinal herbs as potential AChE inhibitors for anti-Alzheimer's disease: A review.
Jiang Y; Gao H; Turdu G
Bioorg Chem; 2017 Dec; 75():50-61. PubMed ID: 28915465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
